Current Ovarian Cancer Maintenance Strategies and Promising New Developments

While ovarian cancer typically responds well to front line treatment, many patients will relapse within 5 years. Treatment options are less effective at each recurrence highlighting the need for novel maintenance therapies. PolyADP-ribose polymerase (PARP) inhibitors have recently gained approval in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Cancer
Autores principales: Gogineni, Vinaya, Morand, Susan, Staats, Hannah, Royfman, Rachel, Devanaboyina, Monika, Einloth, Katelyn, Dever, Danielle, Stanbery, Laura, Aaron, Phylicia, Manning, Luisa, Walter, Adam, Edelman, Gerald, Dworkin, Lance, Nemunaitis, John
Formato: Artigo
Lenguaje:Inglês
Publicado: Ivyspring International Publisher 2021
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7738841/
https://ncbi.nlm.nih.gov/pubmed/33391401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.49406
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares